Table I.
Study participant demographic and clinical characteristics including those completing only one study arm.
| Valacyclovir | Famciclovir | ||
|---|---|---|---|
| Study 1 (n=29) | Study 2 (n=13) | Study 3 (n=16) | |
| Age (years), median (range) | 44 (28 – 53) | 31 (22 – 43) | 36 (29 – 48) |
| Race/Nationality, n (%) | |||
| White | 20 (69) | 3 (23) | 14 (88) |
| Peruvian | 0 | 10 (77) | 0 |
| Black | 7 (24) | 0 | 1 (6) |
| Other | 2 (7) | 0 | 1 (6) |
| Sexual preference, n (%) | |||
| Homosexual | 26 (90) | 13 (100) | 14 (88) |
| Bisexual | 3 (10) | 0 | 2 (13) |
| Days on treatment median (range) | |||
| Placebo | 55 (49 – 64) | 56 (56–56) | 55 (53 – 60) |
| Drug | 56 (51 – 64) | 56 (53 – 56) | 55 (46 – 63) |
| Years since diagnosis median (range) | 10.2 (0.2 – 20.1) | N/A | 5.2 (0.2 – 11.1) |
| Age at diagnosis (years) median (range) | 33 (18 – 47) | N/A | 30 (21 – 43) |
| Antiretroviral use, n (%) | |||
| None | 12 (41) | 13 (100) | 10 (63) |
| Non-HAART | 0 | 0 | 4 (25) |
| HAART | 17 (59) | 0 | 0 |
| Missing | 0 | 0 | 2 (13) |
| CD4 count (cells/μl) median (range) | 351 (85 – 1062) | 380 (232 – 584) | 420 (90 – 921) |
| HIV viral load (log10 copies/ml), median (range) | 1.2 (1.2 – 5.2) | 4.3 (3.4 – 5.1) | 3.8 (2.4 – 5.2) |